Premium
DNA ploidy and survival of patients with clinically localized prostate cancer treated without intent to cure
Author(s) -
Borre Michael,
Høyer Morten,
Nerstrøm Benni,
Overgaard Jens
Publication year - 1998
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/(sici)1097-0045(19980901)36:4<244::aid-pros5>3.0.co;2-f
Subject(s) - prostate cancer , prostate , ploidy , medicine , pathology , cancer , stage (stratigraphy) , flow cytometry , oncology , disease , biology , immunology , genetics , gene , paleontology
BACKGROUND The optimal approach to diagnosis and treatment of localized prostate cancer remains controversial. Deoxyribonucleic acid (DNA) ploidy has been suggested as an important predictor for outcome in prostate cancer. The purpose of this study was to correlate DNA ploidy with disease‐specific survival in patients with clinically localized prostate cancer treated with no intent to cure. METHODS DNA ploidy was determined by flow cytometry in archival formalin fixed, paraffin embedded tumor tissue obtained at diagnosis in 120 patients with clinically localized prostate cancer with a nearly complete follow‐up. RESULTS Ninety (75%) of the tumors were diploid, while only 11 (9%) tumors were categorized as tetraploid. Tumor DNA ploidy (diploid versus nondiploid) significantly associated with histopathological grade ( P = 0.002) and disease‐specific survival ( P = 0.011), while there was no association with tumor stage ( P = 0.054). In a multivariate Cox analysis, histopathological grade ( P = 0.005) was the only significant predictor of disease‐specific death, while analyzing the 96 low‐grade tumors separately, DNA ploidy became significant ( P = 0.024). CONCLUSIONS Flow cytometric determined nondiploidy was associated with disease‐specific death in patients with clinically localized prostate cancer, but DNA ploidy provided additional prognostic information in patients with low‐grade tumors only. Prostate 36:244–249, 1998. © 1998 Wiley‐Liss, Inc.